The National Comprehensive Cancer Network updated its NCNN Clinical Practice Guidelines in Oncology® to include stereotactic body radiation therapy as a treatment option for prostate cancer. CyberKnife Center of Chicago specializes in stereotactic radiosurgery and stereotactic body radiation therapy using CyberKnife® technology. If you are interested in learning more about CyberKnife Center of Chicago, call 331-221-2050 to speak with a representative.

1. I felt totally comfortable. I didn’t have to
go through the pain of surgery and recoup
time or the side effects of surgery. It was so
painless, I kept asking,“Is this thing on?”
- Larry D., prostate cancer patient
“
”
CyberKnife SBRT treats prostate cancer in five or
fewer treatments. SBRT can serve as a primary
treatment or as an additional therapy given after
a different treatment method to lower the risk of
the cancer returning.
CyberKnife® SBRT for Prostate Cancer
ChicagoCK.com - 331-221-2050 - 177 East Brush Hill Road, Elmhurst, IL 60126
National Comprehensive Cancer Network
(NCCN) Guidelines for Prostate Cancer
• In January 2014, the NCCN updated its NCCN
Clinical Practice Guidelines in Oncology® to include
stereotactic body radiation therapy (SBRT) as a
treatment option for prostate cancer. To review the
complete guidelines visit www.NCCN.org.
• NCCN is an alliance of 23 of the world’s leading
cancer centers. These institutions work together to
develop treatment guidelines for many cancers and
are dedicated to research that improves the quality of
cancer care.
• The update to the NCCN Guidelines demonstrates
acceptance and support of SBRT as a treatment option
for prostate cancer from a leading, world-renown
coalition of cancer centers.
• NCCN Guidelines are developed and updated
annually by nearly 950 clinical professionals and
researchers from the NCCN member institutions.
• The guidelines assist individuals involved in
cancercare,suchasphysicians,nurses,patientsand their
families, with the decision-making process and are
intended to advance the fight against cancer.
• The NCCN update follows a 2013 published model
coverage policy by the American Society for Radiation
Oncology(ASTRO).The policy developed by ASTRO helps
insurance companies provide insurance benefits to
men for the treatment of prostate cancer. To review the
complete model policy visit www.astro.org.
The information contained in this document is presented in summary form
only and is not intended to replace or serve as a substitute for your duty to
verify that such information is proper for your patient’s signs, symptoms,
conditions or circumstance(s).